Safety Outcomes Of Darolutamide Vs Apalutamide And Enzalutamide In Nmcrpc

Safety outcomes of darolutamide vs apalutamide and enzalutamide in nmCRPC

ARAMIS: Safety and Efficacy of Darolutamide in nmCRPC

PCa Commentary - nmCRPC and Androgen Receptor Inhibition: Enzalutamide, Apalutamide and Darolutamide

Grand Rounds in Urology

SPARTAN vs. PROSPER: apalutamide or enzalutamide for nmCRPC?

ARAMIS: efficacy and safety of darolutamide in nmCRPC

Interaction of darolutamide with substrates of CYPs and P-gp

Awaiting key results for enzalutamide and apalutamide in nmCRPC

Dr. Saad on the Safety Profile of Apalutamide in M0CRPC

Nonmetastatic CRPC: Considerations for Apalutamide

Considerations for Apalutamide Versus Enzalutamide in Prostate Cancer Treatment

Specialty Pharmacy Times

Assessing the Role of Darolutamide in CRPC

Targeted Oncology

Dr. Chi on Abiraterone Versus Enzalutamide for Metastatic Castration-Resistant Prostate Cancer

Comparing Apalutamide and Enzalutamide in Real-World Treatment of mCSPC

GU Oncology Now

Dr. Bradley on Adverse Events Associated With Enzalutamide and Apalutamide in Prostate Cancer

Kim N. Chi, MD, outlines the safety profile of apalutamide

Dr. Saad on the Clinical Impact of Apalutamide in nmCRPC

TITAN trial

European Association of Urology

Apalutamide, darolutamide and enzalutamide for nonmetastatic castration-resistant prostate cancer.

Overall Survival Data Presented at ASCO 2020 for nmCRPC

PANTHER: apalutamide + abiraterone in Black and White mCRPC patients